News | March 23, 2026
Zydus launches affordable Semaglutide in India after patent expiry
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
Subscribe To Our Newsletter & Stay Updated
